Understanding and treating painful diabetic neuropathy: Time for a paradigm shift

Diabetic Medicine

Volumn 32, Issue 6, 2015, Pages 771-777

  Gandhi, R A ^a   Selvarajah, D ^a  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DULOXETINE; GABAPENTIN; GADOLINIUM; INOSITOL; LAMOTRIGINE; LIDOCAINE; NALOXONE; NORADRENALIN; OXCARBAZEPINE; POTASSIUM CHANNEL; PREGABALIN; SEROTONIN; VOLTAGE GATED CALCIUM CHANNEL;

ALTERNATIVE MEDICINE; ANXIETY; CHANNELOPATHY; CHRONIC PAIN; CLINICAL FEATURE; COGNITIVE THERAPY; CONSTIPATION; DECREASED APPETITE; DEFAULT MODE NETWORK; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLYCEMIC CONTROL; HUMAN; NAUSEA; NERVE INJURY; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERCEPTION; PLACEBO EFFECT; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SOMNOLENCE; XEROSTOMIA; CENTRAL NERVOUS SYSTEM; DIABETIC NEUROPATHIES; NEURALGIA; PHYSIOLOGY;

CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; DIABETIC NEUROPATHIES; HUMANS; NEURALGIA; PLACEBO EFFECT;

EID: 84929519095     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12755     Document Type: Review

References (53)

1. Tesfaye S, Kempler P. Painful diabetic neuropathy. Diabetologia 2005; 48: 805-807.
2. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374-385.
3. Selvarajah D, Cash T, Sankar A, Thomas L, Davies J, Cachia E et al. The contributors of emotional distress in painful diabetic neuropathy. Diab Vasc Dis Res 2014; 11: 218-225.
4. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220-2224.
5. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21: 976-982.
6. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
7. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, Group KS. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10: 393-400.
8. Craner MJ, Klein JP, Renganathan M, Black JA, Waxman SG. Changes of sodium channel expression in experimental painful diabetic neuropathy. Ann Neurol 2002; 52: 786-792.
9. Llewelyn JG, Gilbey SG, Thomas PK, King RH, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain 1991; 114: 867-892.
10. Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128: 169-179.
11. Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006; 20: 34-39.
12. Jarvis B, Coukell AJ. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998; 56: 691-707.
13. Tsantoulas C, Zhu L, Shaifta Y, Grist J, Ward JP, Raouf R et al. Sensory neuron downregulation of the Kv9.1 potassium channel subunit mediates neuropathic pain following nerve injury. J Neurosci 2012; 32: 17502-17513.
14. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009; 60: 84-89.
15. Maier C, Baron R, Tölle TR, Binder A, Birbaumer N, Birklein F et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010; 150: 439-450.
16. Giannini C, Dyck PJ. Pathologic alterations in human diabetic polyneuropathy. In: Dyck PJ, Thomas PK, editors. Diabetic Neuropathy 2nd edn: WB Saunders; 1999. pp. 279-295.
17. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG et al. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996; 39: 329-335.
18. Newrick PG, Wilson AJ, Jakubowski J, Boulton AJ, Ward JD. Sural nerve oxygen tension in diabetes. Br Med J. 1986; 293: 1053-1054.
19. Selvarajah D, Wilkinson ID, Davies J, Gandhi R, Tesfaye S. Central nervous system involvement in diabetic neuropathy. Curr Diab Rep 2011; 11: 310-322.
20. Wilkinson ID, Selvarajah D, Greig M, Shillo P, Boland E, Gandhi R et al. Magnetic resonance imaging of the central nervous system in diabetic neuropathy. Curr Diab Rep 2013; 13: 509-516.
21. Bingel U, Tracey I. Imaging CNS modulation of pain in humans. Physiology 2008; 23: 371-380.
22. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron 2007; 55: 377-391.
23. Gandhi R, Selvarajah D, Emery C, Wilkinson I, Tesfaye S. Neurochemical abnormalities within sensory pathways in the brain in diabetic neuropathy. Diabetologia 2008; 51(Suppl 1): 1-588.
24. Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular perfusion abnormalities of the Thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care 2011; 34: 718-720.
25. Baliki MN, Mansour AR, Baria AT, Apkarian AV. Functional reorganization of the default mode network across chronic pain conditions. PLoS One 2014; 9: e106133.
26. Cauda F, Sacco K, Duca S, Cocito D, D'Agata F, Geminiani GC et al. Altered resting state in diabetic neuropathic pain. PLoS One 2009; 4: e4542.
27. Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002; 19: 870-873.
28. Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M et al. Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management. Diabetes Metab Res Rev 2011; 27: 629-638.
29. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234-241.
30. Kajdasz DK, Iyengar S, Desaiah D, Backonja MM, Farrar JT, Fishbain DA et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007; 29 (Suppl.): 2536-2546.
31. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836.
32. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454.
33. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83: 85-90.
34. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-1846.
35. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
36. Biesbroeck R, Bril V, Hollander P, Kabadi U, Schwartz S, Singh SP et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Ther 1995; 12: 111-120.
37. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-918.
38. National Institute for Health and Clinical Excellence. Neuropathic pain - pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings. November 2013. Available at http://www.nice.org.uk/guidance/cg173 Last accessed 21 February 2015.
39. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(Suppl 3): S3-14.
40. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122(Suppl): S22-32.
41. Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tolle T, Bouhassira D et al. Duloxetine and pregabalin: High-dose monotherapy or their combination? The "COMBO-DN study" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154: 2616-2625.
42. Bouhassira D, Wilhelm S, Schacht A, Perrot S, Kosek E, Cruccu G et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain 2014; 155: 2171-2179.
43. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998; 39: 115-121.
44. Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni MC et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005; 48: 817-823.
45. Hamza MA, White PF, Craig WF, Ghoname ES, Ahmed HE, Proctor TJ et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000; 23: 365-370.
46. Eccleston C, Williams AC, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2009: CD007407.
47. Otis JD, Sanderson K, Hardway C, Pincus M, Tun C, Soumekh S. A randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy. J Pain 2013; 14: 475-482.
48. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010; 33: 128-130.
49. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686-695.
50. Arnold MH, Finniss DG, Kerridge I. Medicine's inconvenient truth: the placebo and nocebo effect. Intern Med J 2014; 44: 398-405.
51. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci 2005; 25: 10390-10402.
52. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 2004; 303: 1162-1177.
53. Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009; 63: 533-543.